Supplementary file 1_Lycii radicis cortex alleviates fibrosis in hiPSC-derived multilineage hepatic organoids via the cAMP-PKA pathway.zip

Background<p>Liver fibrosis, driven by excessive extracellular matrix (ECM) deposition and activation of hepatic stellate cells (HSCs), still lacks effective therapies, partly due to the absence of human-relevant models. Lycii Radicis Cortex (LRC), a traditional Chinese medicine, exhibits repo...

全面介绍

Saved in:
书目详细资料
主要作者: Junming Xu (1716112) (author)
其他作者: Xiaopu Sang (8502954) (author), Yongfei He (21372968) (author), Jie Ke (2005411) (author), Jiasen Xu (729951) (author), Tanbin Liu (4849807) (author), Jicai Wang (21372977) (author), Hang Zhai (1540051) (author), Xiaoni Chen (8502957) (author), Xianjie Shi (3567419) (author), Fenfang Wu (3157299) (author)
出版: 2025
主题:
标签: 添加标签
没有标签, 成为第一个标记此记录!
实物特征
总结:Background<p>Liver fibrosis, driven by excessive extracellular matrix (ECM) deposition and activation of hepatic stellate cells (HSCs), still lacks effective therapies, partly due to the absence of human-relevant models. Lycii Radicis Cortex (LRC), a traditional Chinese medicine, exhibits reported anti-inflammatory and antioxidant activities, yet its anti-fibrotic potential has not been validated in human organoid-based systems.</p>Methods<p>We established hiPSC-derived multilineage hepatobiliary organoids (mHBOs) containing mesoderm-derived HSCs and implemented a TGF-β–induced fibrosis model within this platform. Using mHBOs alongside a CCl4-injury mouse model, we assessed the anti-fibrotic activity of LRC, and investigated underlying mechanisms.</p>Results<p>LRC significantly attenuated fibrosis in mHBOs and in CCl<sub>4</sub>-injured mice, reducing ECM accumulation and HSC activation. In mHBOs, LRC activated the cAMP–PKA–CREB pathway, thereby suppressing HSC activation and reducing parenchymal apoptosis; these effects were reversed by PKA inhibition.</p>Conclusion<p>LRC exhibits potent anti-fibrotic activity in a physiologically relevant human organoid model, providing mechanistic insight into HSC regulation and supporting its potential as a candidate therapy for chronic liver disease. Furthermore, this study introduces a translational platform integrating animal models and hiPSC-derived organoids to facilitate anti-fibrotic drug discovery and evaluation.</p>